The maker of Wegovy and Ozempic, Novo Nordisk, has predicted a sharp drop in revenues this year owing to what its boss described as a "painful" push by Donald Trump to lower U.S. weight-loss drug prices, rising competition, and the loss of important patent protections. Denmark's Novo, once the poster-child for the growth in weight-loss treatments, said sales this year were likely to fall between 5% and 13%, ending years of double-digit gains, despite the promising launch of its new Wegovy pill in the U.S. Its share price plummeted 17% on Wednesday, erasing all gains so far this year. In the past year the stock has lost nearly 50% of its value.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
